A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study

Drug Des Devel Ther. 2019 Jan 24:13:477-479. doi: 10.2147/DDDT.S192124. eCollection 2019.
No abstract available

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Anti-HIV Agents / pharmacology*
  • Atazanavir Sulfate / pharmacology*
  • Female
  • HIV Infections / drug therapy*
  • HIV Infections / metabolism
  • HIV Reverse Transcriptase / antagonists & inhibitors*
  • HIV Reverse Transcriptase / metabolism
  • Heterocyclic Compounds, 3-Ring / pharmacology*
  • Humans
  • Male
  • Middle Aged
  • Oxazines
  • Pilot Projects
  • Piperazines
  • Prospective Studies
  • Pyridones
  • Reverse Transcriptase Inhibitors / pharmacology*
  • Ritonavir / pharmacology*

Substances

  • Anti-HIV Agents
  • Heterocyclic Compounds, 3-Ring
  • Oxazines
  • Piperazines
  • Pyridones
  • Reverse Transcriptase Inhibitors
  • Atazanavir Sulfate
  • dolutegravir
  • HIV Reverse Transcriptase
  • Ritonavir